aTyr Pharma (ATYR) Osake Kurssi
aTyr Pharma Kurssi
aTyr Pharman liikevaihto on supistunut 12,5 % vuodessa viimeisten 6 vuoden aikana 190 000,00 USD:een. aTyr Pharman nettomarginaali on nyt −39 009,5 %, laskenut −155,2 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 1,25 USD, eli ali nykyhintaa 74,7 %. 15 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Osta.
aTyr Pharma osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
aTyr Pharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset aTyr Pharma -osakkeesta
The business model of aTyr Pharma Inc is focused on discovering and developing first-in-class medicines based on its knowledge of tRNA synthetase biology. By leveraging their expertise in this field, aTyr Pharma aims to harness the potential of these proteins to develop innovative therapies for a range of rare and severe immune and tissue-related diseases. With a dedicated team and a strong pipeline of product candidates, aTyr Pharma is actively working towards addressing unmet medical needs and improving patient outcomes in various therapeutic areas.
aTyr Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of aTyr Pharma Inc in the market include other pharmaceutical companies in the biotechnology industry. Some notable competitors in the field of developing protein therapeutics and novel drugs similar to aTyr Pharma Inc are Genentech, Novartis, Gilead Sciences, and Regeneron Pharmaceuticals. These companies are recognized for their innovations and advancements in the biotech sector, competing with aTyr Pharma Inc by offering alternative treatments and solutions in the market. However, aTyr Pharma Inc distinguishes itself through its unique approach to discovering and developing Physiocrine-based therapeutics for severe rare diseases.
aTyr Pharma Inc is a biotechnology company founded in 2005. Headquartered in San Diego, California, aTyr Pharma is focused on developing innovative therapeutics based on the physiological relevance of tRNA synthetases. The company aims to treat severe rare diseases and immune disorders by targeting these enzymes. With a strong commitment to research and development, aTyr Pharma has made significant advancements in understanding the role of tRNA synthetases in human biology. By leveraging this knowledge, aTyr Pharma aims to provide effective and targeted treatments for patients in need. Through its dedication to scientific innovation, aTyr Pharma Inc has become a leading player in the biotech industry.
aTyr Pharma Inc has achieved several significant milestones throughout its history. One major milestone includes the successful completion of a Phase 1b/2 clinical trial for its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis. Additionally, the company has secured partnerships and collaborations with renowned pharmaceutical companies, such as Kyorin Pharmaceutical Co., Ltd. These collaborations have played a crucial role in advancing aTyr Pharma's research and development efforts. Moreover, aTyr Pharma has also received recognition through various industry awards and acknowledgments for its innovative approach to developing novel therapeutics. These milestones highlight aTyr Pharma Inc's continued dedication to advancing and revolutionizing the field of immunology and rare diseases.
aTyr Pharma Inc is primarily present in the United States.
aTyr Pharma Inc represents a strong commitment to innovation, scientific excellence, and improving patient lives. With its corporate philosophy centered around revolutionizing the discovery and development of protein-based therapeutics, aTyr Pharma Inc is dedicated to leveraging its expertise in the field of Physiocrine biology. By focusing on developing potential treatments for rare diseases, this biotechnology company aims to address unmet medical needs and make a meaningful impact in the healthcare industry. aTyr Pharma Inc's emphasis on advanced research and cutting-edge technologies further reinforces its dedication to advancing medicine and enhancing patients' quality of life.
Analyytikot asettavat tällä hetkellä aTyr Pharma-osakkeelle keskimääräisen tavoitehinnan 5,13 USD (mediaani: 1,25 USD), mikä merkitsee +3,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 15 analyytikkoarvioon.
15 analyytikkoa arvioi tällä hetkellä aTyr Pharma-osaketta: 9 suosittaa ostoa, 6 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla aTyr Pharma-osake noteerataan hintaan 4,43 EUR (4,94 USD).
aTyr Pharma-osake (ATYR) on listattuna 3 pörssissä, muun muassa: NASDAQ (LIFE), Frankfurt (471A.F), München (471A.MU).
aTyr Pharma Inc. is a biopharmaceutical company that focuses on innovative therapeutic approaches for the treatment of rare metabolic and autoimmune diseases. The company is dedicated to developing protein therapeutics derived from natural immunomodulatory proteins and integrates the latest biochemical and physiological findings from academia into its technology platform and preclinical development programs. aTyr Pharma follows a diversified business strategy to develop and bring its product candidates to market. This includes collaborations with other biotech and pharmaceutical companies, as well as the submission of applications for government grants and funding. One of aTyr Pharma Inc.'s main products currently is the drug Resolaris for the treatment of rare muscle diseases such as facioscapulohumeral muscular dystrophy (FSHD). The company is conducting clinical trials to establish Resolaris as an effective and meaningful treatment method in this area. Additionally, aTyr Pharma plans to develop further therapeutics based on its unique protein platform. Another important element of aTyr Pharma Inc.'s business model is close collaboration with key players in the industry, including research institutions and partner companies. The company has already formed several strategic partnerships and collaborations with other biotech and pharmaceutical companies to advance the development and commercialization of its products. These partnerships enable the utilization of existing synergies and help reduce the risk in the development of new products. Furthermore, the company has a clear expansion strategy to extend its therapeutic approaches to new indication areas such as rare metabolic diseases. The existing knowledge and experience in drug development will be utilized to ultimately address market gaps and offer a broader product range. aTyr Pharma pursues a comprehensive research strategy and invests significant resources in researching and developing new approaches for the treatment of rare and severe diseases. Protein-based science has proven to be a relevant platform in recent years, and there is considerable potential in its effective implementation. Overall, aTyr Pharma Inc. has established itself as an innovative biotech company specializing in the development of protein-based therapeutics. The business strategy, the incorporation of partnerships and collaborations, and the emphasis on research and development form the basis for the successful advancement of the company.
Liikevaihtoa ei voida laskea aTyr Pharma:lle tällä hetkellä.
odotettu voitto aTyr Pharma on −40,73 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
aTyr Pharma:n hinta-voitto-suhde (P/E) on tällä hetkellä −11,89. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan aTyr Pharma-osakkeen arvostusta.
P/S-suhdetta ei voida laskea aTyr Pharma:lle tällä hetkellä.
aTyr Pharma:n Eulpool-laatuscore on 4/10.
aTyr Pharma:n ISIN on US0021202025. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
aTyr Pharma:n WKN on A2PM86. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
aTyr Pharma:n ticker on ATYR. Tämä pörssinoteeraus käytetään aTyr Pharma-osakkeiden kauppaan pörssissä.
aTyr Pharma osake
aTyr Pharma vertaisryhmä
aTyr Pharma Ticker
aTyr Pharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi aTyr Pharma:sta
Meidän osakeanalyysimme aTyr Pharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut aTyr Pharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: